PsiOxus-Therapeutics News-Web-12_edited.jpg

Our News

Read about our latest news, events and updates

September 15, 2021

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

April 14, 2021

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

April 7, 2021

PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration

March 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer

March 13, 2019

PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.